Clinical trial
Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049)
NCT00449930 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00449930 |
|---|---|
| Title | Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049) |
| Official title | A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Metformin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | sitagliptin phosphate, Comparator: metformin hydrochloride |
| Enrollment | 1,050 |
| Start date | Mar 1, 2007 |
| Primary completion | Jul 25, 2008 |
| Completion | Jul 25, 2008 |
| First posted | Mar 21, 2007 |
| Last update posted | May 11, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: